Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03352414 · ClinicalTrials.gov registry record · Phase 2
Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC
A Phase 2 study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT03352414 is a Phase 2 study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 84 participants.
The verdict
NCT03352414, a Phase 2 study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the ability of alvimopan to reduce the time to return of bowel function in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Half of the participants will receive alvimopan or and half will receive placebo immediately before and for up to seven days after surgery.
Interventions
- DRUG Placebo
- DRUG Alvimopan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2018-03-08 |
| Est. Completion | 2020-04-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03352414
The ClinicalTrials.gov registry entry for NCT03352414 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03352414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03352414 about?
NCT03352414 is a clinical study titled "Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC". The purpose of this study is to investigate the ability of alvimopan to reduce the time to return of bowel function in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Half of the participants will receive alvimopan or and half will receive placebo immediately...
What is the current status of trial NCT03352414?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2018-03-08. Estimated completion is 2020-04-28.
What interventions are being tested in trial NCT03352414?
The interventions under investigation include: Placebo (DRUG), Alvimopan (DRUG).
Who is sponsoring clinical trial NCT03352414?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.